.

Deeper Knowledge, Faster

  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
QuintilesIMS
Cerilliant
Chinese Patent Office
US Department of Justice
Queensland Health
Cipla
Dow
Novartis
Julphar

Generated: June 25, 2017

DrugPatentWatch Database Preview

CARDURA Drug Profile

« Back to Dashboard

What is the patent landscape for Cardura, and when can generic versions of Cardura launch?

Cardura is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in CARDURA is doxazosin mesylate. There are thirteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

Summary for Tradename: CARDURA

Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list3
Bulk Api Vendors: see list102
Clinical Trials: see list9
Patent Applications: see list1,377
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CARDURA at DailyMed

Pharmacology for Tradename: CARDURA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-001Nov 2, 1990ABRXYesYes► Subscribe► Subscribe
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-004Nov 2, 1990ABRXYesNo► Subscribe► Subscribe
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-002Nov 2, 1990ABRXYesNo► Subscribe► Subscribe
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-003Nov 2, 1990ABRXYesNo► Subscribe► Subscribe
Pfizer
CARDURA XL
doxazosin mesylate
TABLET, EXTENDED RELEASE;ORAL021269-002Feb 22, 2005RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CARDURA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-004Nov 2, 19904,188,390► Subscribe
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-001Nov 2, 19904,188,390► Subscribe
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-003Nov 2, 19904,188,390► Subscribe
Pfizer
CARDURA
doxazosin mesylate
TABLET;ORAL019668-002Nov 2, 19904,188,390► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Cantor Fitzgerald
Mallinckrodt
Covington
UBS
Federal Trade Commission
Queensland Health
Julphar
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot